Movement Alert｜Tempus AI Rises 5.67% in Regular Trading, Life Sciences Sector Rallies as Recent FDA Approval and AI Platform Launch Catalyze Gains

Market Focus06-25 22:07

On June 25, Tempus AI rose 5.67% in regular trading, reaching $54.30 per share with turnover of $131 million, extending gains from the prior session.

The rally was driven by a confluence of recent catalysts. The company's xT CDx next-generation sequencing platform recently received FDA approval for tumor-only comprehensive genomic profiling of solid tumors, making Tempus the first laboratory with FDA companion diagnostic approval for both tumor-only and tumor-normal genomic profiling. The approval is expected to deliver an estimated $200 increase in average selling price starting next year. Additionally, the company launched Lens, a next-generation agentic AI platform for oncology drug development designed to help teams optimize clinical trial designs and accelerate evidence generation.

The broader Life Sciences Tools and Services sector rallied in tandem, with Bio-Techne up 19.33%, Repligen up 5.76%, Thermo Fisher Scientific up 4.13%, Danaher up 4.09%, and West Pharmaceutical up 2.67%, providing further sector-wide tailwinds.

(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1135534720?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-06-25 22:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1135534720","market":"hk","top_or_hot":-1,"title":"Movement Alert｜Tempus AI Rises 5.67% in Regular Trading, Life Sciences Sector Rallies as Recent FDA Approval and AI Platform Launch Catalyze Gains","media":"Market Focus","content":"<p><p>On June 25, Tempus AI rose 5.67% in regular trading, reaching $54.30 per share with turnover of $131 million, extending gains from the prior session.</p><p>The rally was driven by a confluence of recent catalysts. The company's xT CDx next-generation sequencing platform recently received FDA approval for tumor-only comprehensive genomic profiling of solid tumors, making Tempus the first laboratory with FDA companion diagnostic approval for both tumor-only and tumor-normal genomic profiling. The approval is expected to deliver an estimated $200 increase in average selling price starting next year. Additionally, the company launched Lens, a next-generation agentic AI platform for oncology drug development designed to help teams optimize clinical trial designs and accelerate evidence generation.</p><p>The broader Life Sciences Tools and Services sector rallied in tandem, with Bio-Techne up 19.33%, Repligen up 5.76%, Thermo Fisher Scientific up 4.13%, Danaher up 4.09%, and West Pharmaceutical up 2.67%, providing further sector-wide tailwinds.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Movement Alert｜Tempus AI Rises 5.67% in Regular Trading, Life Sciences Sector Rallies as Recent FDA Approval and AI Platform Launch Catalyze Gains</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nMovement Alert｜Tempus AI Rises 5.67% in Regular Trading, Life Sciences Sector Rallies as Recent FDA Approval and AI Platform Launch Catalyze Gains\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1054767329\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Market Focus </p>\n<p class=\"h-time\">2026-06-25 22:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p><p>On June 25, Tempus AI rose 5.67% in regular trading, reaching $54.30 per share with turnover of $131 million, extending gains from the prior session.</p><p>The rally was driven by a confluence of recent catalysts. The company's xT CDx next-generation sequencing platform recently received FDA approval for tumor-only comprehensive genomic profiling of solid tumors, making Tempus the first laboratory with FDA companion diagnostic approval for both tumor-only and tumor-normal genomic profiling. The approval is expected to deliver an estimated $200 increase in average selling price starting next year. Additionally, the company launched Lens, a next-generation agentic AI platform for oncology drug development designed to help teams optimize clinical trial designs and accelerate evidence generation.</p><p>The broader Life Sciences Tools and Services sector rallied in tandem, with Bio-Techne up 19.33%, Repligen up 5.76%, Thermo Fisher Scientific up 4.13%, Danaher up 4.09%, and West Pharmaceutical up 2.67%, providing further sector-wide tailwinds.</p><p>(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)</p></p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"TEM","symbol_name":"Tempus AI","start_time":0,"source_url":"","article_id":"1135534720","we_media_id":"1054767329","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1135534720","pubTimestamp":1782396475,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Market Focus","introduction":"Track stock‘s movements and relevant news","home_visible":1,"id":"1054767329","head_image":"https://static.tigerbbs.com/51943b2858f75e05ca2ebb144b4e626a"},"summary":"On June 25, Tempus AI rose 5.67% in regular trading, reaching $54.30 per share with turnover of $131 million, extending gains from the prior session.The rally was driven by a confluence of recent...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"TEM":"Tempus AI"},"translate_title":"动向提示|腾邦AI常规交易上涨5.67%，生命科学板块因近期FDA批准和AI平台推出催化涨势而上涨","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TEM":1},"content_text":"On June 25, Tempus AI rose 5.67% in regular trading, reaching $54.30 per share with turnover of $131 million, extending gains from the prior session.The rally was driven by a confluence of recent catalysts. The company's xT CDx next-generation sequencing platform recently received FDA approval for tumor-only comprehensive genomic profiling of solid tumors, making Tempus the first laboratory with FDA companion diagnostic approval for both tumor-only and tumor-normal genomic profiling. The approval is expected to deliver an estimated $200 increase in average selling price starting next year. Additionally, the company launched Lens, a next-generation agentic AI platform for oncology drug development designed to help teams optimize clinical trial designs and accelerate evidence generation.The broader Life Sciences Tools and Services sector rallied in tandem, with Bio-Techne up 19.33%, Repligen up 5.76%, Thermo Fisher Scientific up 4.13%, Danaher up 4.09%, and West Pharmaceutical up 2.67%, providing further sector-wide tailwinds.(The above content is based on publicly available market information, generated by a program or algorithm, and is intended solely as a stock movement alert. It does not constitute investment advice or a basis for trading decisions.)","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.0","shortVersion":"4.44.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1135534720","isCrawlerRequest":true}